As demonstrated above, an increasing number of transplant centres have proposed to withdraw or avoid steroids, nevertheless calcineurin inhibitors have remained the backbone of most immunosuppressive protocols. The use of antibody induction therapy for pancreas transplant recipients has been guided by practical experience, in the absence of randomised prospective trials.8 A multicenter trial involving 130 kidney transplant recipients has started in our center, investigating the safety and efficacy of Campath-1H in combination with Tacrolimus monotherapy compared to a standard Tacrolimus/MMF/steroid regimen, demonstrating excellent results with virtually no complications or side effects with Tacrolimus monotherapy after Campath-1H induction. Based on the existing clinical trials and the experience of Campath-1H therapy in our center we would like to investigate the long-term safety and efficacy of Campath-1H induction and Tacrolimus monotherapy compared to a standard regimen with ATG induction, Tacrolimus, MMF and short term steroids in a controlled, prospective, randomised trial.